Table 1 End points of the simulated 18-month clinical trial
From: Individual bioenergetic capacity as a potential source of resilience to Alzheimer’s disease
All genotypes | Genotypes [slower decline] | |||
|---|---|---|---|---|
Outcome | 0–25% quartile | 75–100% quartile | 0–25% quartile | 75–100% quartile |
CDR-SB | ||||
Adjusted mean change | 0.906 | 1.441 | 0.751 | 1.647 |
Adjusted mean change difference | −0.534 (−0.816 to −0.252) | −0.896 (−1.285 to −0.507) | ||
P value | 2.14 × 10−4 | 7.09 × 10−6 | ||
ADAS-Cog. 13 | ||||
Adjusted mean change | 2.520 | 3.942 | 2.317 | 4.680 |
Adjusted mean change difference | −1.422 (−2.458 to −0.387) | −2.362 (−3.805 to −0.920) | ||
P value | 7.14 × 10−3 | 1.37 × 10−3 | ||
MMSE | ||||
Adjusted mean change | −1.061 | −1.803 | −0.738 | −2.086 |
Adjusted mean change difference | 0.742 (0.246 to 1.237) | 1.349 (0.669 to 2.028) | ||
P value | 3.39 × 10−3 | 1.07 × 10−4 | ||
FAQ | ||||
Adjusted mean change | 2.542 | 3.999 | 2.146 | 4.104 |
Adjusted mean change difference | −1.458 (−2.202 to −0.713) | −1.958 (−2.996 to −0.919) | ||
P value | 1.32 × 10−4 | 2.32 × 10−4 | ||
